Envestnet Asset Management Inc. decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 79.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,989 shares of the medical equipment provider’s stock after selling 312,545 shares during the quarter. Envestnet Asset Management Inc. owned about 0.12% of Lantheus worth $6,629,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. Fairfield Bush & CO. acquired a new position in shares of Lantheus during the 1st quarter valued at $177,000. Raymond James & Associates acquired a new position in shares of Lantheus during the 1st quarter valued at $856,000. Bank of New York Mellon Corp lifted its holdings in shares of Lantheus by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock valued at $34,791,000 after acquiring an additional 16,422 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Lantheus by 14.4% during the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock valued at $1,064,000 after acquiring an additional 2,427 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in shares of Lantheus during the 1st quarter valued at $354,000. Institutional investors and hedge funds own 99.06% of the company’s stock.
Lantheus Stock Performance
Shares of Lantheus stock opened at $68.20 on Friday. The firm has a market cap of $4.67 billion, a PE ratio of 47.69 and a beta of 0.66. The firm’s 50-day simple moving average is $66.53 and its 200-day simple moving average is $77.25. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.05 and a current ratio of 5.37. Lantheus Holdings, Inc. has a 1 year low of $47.46 and a 1 year high of $100.85.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on LNTH shares. Truist Financial reiterated a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a report on Wednesday, October 4th. JMP Securities cut their price objective on shares of Lantheus from $130.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, November 3rd. B. Riley reiterated a “buy” rating and issued a $113.00 price objective on shares of Lantheus in a report on Tuesday, October 3rd. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Monday, November 6th. Finally, William Blair started coverage on shares of Lantheus in a report on Friday, September 29th. They issued an “outperform” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus presently has an average rating of “Buy” and an average price target of $115.00.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.
- Five stocks we like better than Lantheus
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 large caps with red hot RSIs with upside
- What is a Mid Cap Stock? How to Invest
- Johnson Controls International: Nothing but upside for investors
- Do ETFs Pay Dividends? What You Need to Know
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.